Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic
出版年份 2016 全文链接
标题
Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF UROLOGY
Volume 23, Issue 8, Pages 654-665
出版商
Wiley
发表日期
2016-06-15
DOI
10.1111/iju.13137
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer
- (2015) Consuelo Buttigliero et al. CANCER TREATMENT REVIEWS
- The hallmarks of castration-resistant prostate cancers
- (2015) Maria Katsogiannou et al. CANCER TREATMENT REVIEWS
- Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer
- (2015) M. Kato et al. CLINICAL CANCER RESEARCH
- Targeting the adaptive molecular landscape of castration-resistant prostate cancer
- (2015) A. W. Wyatt et al. EMBO Molecular Medicine
- A Randomised Phase 2 Trial of Dexamethasone Versus Prednisolone in Castration-resistant Prostate Cancer
- (2015) Ramachandran Venkitaraman et al. EUROPEAN UROLOGY
- ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
- (2015) Karim Fizazi et al. Expert Review of Anticancer Therapy
- Novel agents for castration-resistant prostate cancer: Early experience and beyond
- (2015) Naohiro Fujimoto INTERNATIONAL JOURNAL OF UROLOGY
- Direct effects of the selective CYP17 lyase (L) inhibitor, VT-464, on the androgen receptor (AR) and its oral activity in an F876L tumor mouse xenograft model.
- (2015) William R. Moore et al. JOURNAL OF CLINICAL ONCOLOGY
- AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC).
- (2015) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery and Development of Galeterone (TOK-001 or VN/124-1) for the Treatment of All Stages of Prostate Cancer
- (2015) Vincent C. O. Njar et al. JOURNAL OF MEDICINAL CHEMISTRY
- Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naive and Castration-Resistant Metastatic Prostate Cancer
- (2015) S. P. Rowe et al. JOURNAL OF NUCLEAR MEDICINE
- Galeterone activity in castration-resistant prostate cancer
- (2015) Farhat Yaqub LANCET ONCOLOGY
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
- (2015) Zhenfei Li et al. NATURE
- Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer
- (2015) Fred Saad et al. UROLOGY
- The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer
- (2015) Shusuke Akamatsu et al. Cell Reports
- Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2015) Emmanuel S. Antonarakis et al. JAMA Oncology
- High Progesterone Receptor Expression in Prostate Cancer Is Associated with Clinical Failure
- (2015) Thea Grindstad et al. PLoS One
- Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
- (2015) Anu-Maarit Moilanen et al. Scientific Reports
- Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation
- (2014) Jonathan I. Epstein et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer
- (2014) Maria Thadani-Mulero et al. CANCER RESEARCH
- Galeterone Prevents Androgen Receptor Binding to Chromatin and Enhances Degradation of Mutant Androgen Receptor
- (2014) Z. Yu et al. CLINICAL CANCER RESEARCH
- Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer
- (2014) C. Liu et al. CLINICAL CANCER RESEARCH
- Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer
- (2014) P. J. Toren et al. MOLECULAR CANCER THERAPEUTICS
- Molecular analysis of circulating tumour cells—biology and biomarkers
- (2014) Matthew G. Krebs et al. Nature Reviews Clinical Oncology
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucocorticoid Receptor Activity Contributes to Resistance to Androgen-Targeted Therapy in Prostate Cancer
- (2014) Masis Isikbay et al. Hormones & Cancer
- Castration-resistant prostate cancer: latest evidence and therapeutic implications
- (2014) Daniel L. Suzman et al. Therapeutic Advances in Medical Oncology
- Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
- (2013) Y. Loriot et al. ANNALS OF ONCOLOGY
- Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
- (2013) K. L. Noonan et al. ANNALS OF ONCOLOGY
- Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment
- (2013) Sushil Badrising et al. CANCER
- The Steroid Receptor Coactivator-3 Is Required for the Development of Castration-Resistant Prostate Cancer
- (2013) Jean C-Y. Tien et al. CANCER RESEARCH
- Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
- (2013) Vivek K. Arora et al. CELL
- A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer
- (2013) Kai-Hsiung Chang et al. CELL
- Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer
- (2013) R.J. van Soest et al. EUROPEAN JOURNAL OF CANCER
- Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
- (2013) D. Bianchini et al. EUROPEAN JOURNAL OF CANCER
- Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone
- (2013) Andres Jan Schrader et al. EUROPEAN UROLOGY
- Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents
- (2013) Carmel J. Pezaro et al. EUROPEAN UROLOGY
- Expression and Function of the Progesterone Receptor in Human Prostate Stroma Provide Novel Insights to Cell Proliferation Control
- (2013) Yue Yu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- An androgen receptor N-terminal domain antagonist for treating prostate cancer
- (2013) Jae-Kyung Myung et al. JOURNAL OF CLINICAL INVESTIGATION
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating tumor cells: Advances in isolation and analysis, and challenges for clinical applications
- (2013) Ramdane Harouaka et al. PHARMACOLOGY & THERAPEUTICS
- Bone Metastases in Castration-Resistant Prostate Cancer: Associations between Morphologic CT Patterns, Glycolytic Activity, and Androgen Receptor Expression on PET and Overall Survival
- (2013) Hebert Alberto Vargas et al. RADIOLOGY
- An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
- (2013) M. Korpal et al. Cancer Discovery
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
- (2013) J. D. Joseph et al. Cancer Discovery
- Overcoming mutation-based resistance to antiandrogens with rational drug design
- (2013) Minna D Balbas et al. eLife
- Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
- (2012) J. Mezynski et al. ANNALS OF ONCOLOGY
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
- (2012) R. Hu et al. CANCER RESEARCH
- FoxA1 Specifies Unique Androgen and Glucocorticoid Receptor Binding Events in Prostate Cancer Cells
- (2012) B. Sahu et al. CANCER RESEARCH
- Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines
- (2012) Y. Li et al. CANCER RESEARCH
- Intratumor Heterogeneity: Evolution through Space and Time
- (2012) C. Swanton CANCER RESEARCH
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- Androgen receptor (AR) aberrations in castration-resistant prostate cancer
- (2012) Kati K. Waltering et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Clonal evolution in cancer
- (2012) Mel Greaves et al. NATURE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Measuring Oncogenic Signaling Pathways in Cancer with PET: An Emerging Paradigm from Studies in Castration-Resistant Prostate Cancer
- (2012) Michael J. Evans Cancer Discovery
- Imaging Androgen Receptor Signaling with a Radiotracer Targeting Free Prostate-Specific Antigen
- (2012) David Ulmert et al. Cancer Discovery
- Circulating Tumor Cells and Circulating Tumor DNA
- (2011) Catherine Alix-Panabières et al. Annual Review of Medicine
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Small Molecule Inhibitors Targeting the “Achilles' Heel” of Androgen Receptor Activity: Figure 1.
- (2011) Marianne D. Sadar CANCER RESEARCH
- Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors
- (2011) C. Cai et al. CANCER RESEARCH
- Androgen receptor and its splice variants in prostate cancer
- (2011) Simon Haile et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants
- (2011) Elahe A. Mostaghel et al. CLINICAL CANCER RESEARCH
- Molecular Alterations during Progression of Prostate Cancer to Androgen Independence
- (2011) P. Saraon et al. CLINICAL CHEMISTRY
- ERG–TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin
- (2011) Sean R Williamson et al. MODERN PATHOLOGY
- Intrinsic disorder in the androgen receptor: identification, characterisation and drugability
- (2011) Iain J. McEwan Molecular BioSystems
- The changing therapeutic landscape of castration-resistant prostate cancer
- (2011) Timothy A. Yap et al. Nature Reviews Clinical Oncology
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival
- (2011) Emma Hörnberg et al. PLoS One
- Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
- (2011) Xiaotun Zhang et al. PLoS One
- Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen
- (2011) M. J. Evans et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer
- (2011) Marianne D. Sadar WORLD JOURNAL OF UROLOGY
- Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
- (2010) Raymond J. Andersen et al. CANCER CELL
- Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
- (2010) M.-L. Zhu et al. CANCER RESEARCH
- An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors
- (2010) Eric J. Lepin et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
- (2010) Shihua Sun et al. JOURNAL OF CLINICAL INVESTIGATION
- Pharmacokinetic Assessment of the Uptake of 16 -18F-Fluoro-5 -Dihydrotestosterone (FDHT) in Prostate Tumors as Measured by PET
- (2010) B. J. Beattie et al. JOURNAL OF NUCLEAR MEDICINE
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Drug safety is a barrier to the discovery and development of new androgen receptor antagonists
- (2010) William R. Foster et al. PROSTATE
- Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer
- (2009) S. M. Hillier et al. CANCER RESEARCH
- A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth
- (2009) Z. Guo et al. CANCER RESEARCH
- Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer
- (2009) D. Sarker et al. CLINICAL CANCER RESEARCH
- Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody
- (2009) Jason P. Gleghorn et al. LAB ON A CHIP
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance
- (2008) S. M. Dehm et al. CANCER RESEARCH
- Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate Cancer
- (2008) J. A. Locke et al. CANCER RESEARCH
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
- (2008) R. Hu et al. CANCER RESEARCH
- Humanized Radioiodinated Minibody For Imaging of Prostate Stem Cell Antigen-Expressing Tumors
- (2008) J. V. Leyton et al. CLINICAL CANCER RESEARCH
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
- (2008) J. S. de Bono et al. CLINICAL CANCER RESEARCH
- Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate Cancer
- (2008) Ying Chen et al. JOURNAL OF MEDICINAL CHEMISTRY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started